Fourth, the clinical cohorts analyzed lack detailed longitudinal sodium-level measurements or pharmacological interventions targeting sodium transporters, precluding an assessment of dynamic sodium dysregulation during BC progression. The gene discussed is SLC5A4; the disease is breast cancer.